Most Read Articles
13 Sep 2020
Regardless of birth weight, being obese at preschool age is associated with a greater risk of elevated blood pressure during early childhood, a recent China study has found. A longer duration of breastfeeding appears to help mitigate such a risk.
Jairia Dela Cruz, 4 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
6 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.


Teprotumumab improves outcomes in thyroid eye disease

11 Mar 2020

Treatment with teprotumumab in patients with active thyroid eye disease confers beneficial effects on proptosis, Clinical Activity Score, diplopia and quality of life, without increasing the incidence of serious adverse events, according to the results of a phase III trial.

A total of 83 patients were randomized to receive teprotumumab (n=41) or placebo (n=42). Treatment was administered as intravenous infusions, with the active drug dosed at 10 mg/kg of body weight for the first infusion and 20 mg/kg for subsequent infusions, once every 3 weeks for 21 weeks. The last trial visit for the present analysis was at week 24.

The primary outcome of a proptosis response (reduction of ≥2 mm) at week 24 occurred with greater frequency in the teprotumumab vs placebo arm (83 percent vs 10 percent; p<0.001), with a number needed to treat of 1.36.

Results for all secondary outcomes were likewise more favourable with the active drug than with placebo: overall response (78 percent vs 7 percent), Clinical Activity Score of 0 or 1 (no or minimal inflammation; 59 percent vs 21 percent), the mean change in proptosis (−2.82 vs −0.54 mm), diplopia response (reduction of ≥1 grade; 68 percent vs 29 percent), and the mean change in Graves’ ophthalmopathy-specific quality-of-life overall score (13.79 vs 4.43 points; pall≤0.001).

Among patients who underwent orbital imaging, six showed improvements in extraocular muscle, orbital fat volume, or both.

Most adverse events were mild or moderate in severity; two serious events occurred in the teprotumumab group, of which one (an infusion reaction) led to treatment discontinuation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Sep 2020
Regardless of birth weight, being obese at preschool age is associated with a greater risk of elevated blood pressure during early childhood, a recent China study has found. A longer duration of breastfeeding appears to help mitigate such a risk.
Jairia Dela Cruz, 4 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
6 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.